Microba Life SciencesASX:MAP -2.63% Net Debt Paydown Yield % is -1.32% as of Jul. 09, 2026. The stock has 6 warning signs investors should review. Among 198 Medical Diagnostics & Research companies, Microba Life Sciences ranks worse than 68.18% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Microba Life Sciences's Net Debt Paydown Yield % was -1.32%.
Microba Life Sciences (ASX:MAP) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Microba Life Sciences Net Debt Paydown Yield % Related Terms
Microba Life Sciences Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences Net Debt Paydown Yield % Chart
ASX:MAP vs TMO, DHR, IDXX: Net Debt Paydown Yield % Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences Net Debt Paydown Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of -1.32% mean?
Microba Life Sciences (ASX:MAP) has a Net Debt Paydown Yield % of -1.32% as of Jul. 09, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Microba Life Sciences and its competitors. According to the industry distribution chart, Microba Life Sciences ranks #135 out of 198 companies in the Medical Diagnostics & Research industry, placing it in the top 68.2%.
Is Microba Life Sciences' Net Debt Paydown Yield % too high?
Microba Life Sciences' current Net Debt Paydown Yield % is -1.32%. Based on the distribution chart, Microba Life Sciences ranks #135 out of 198 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Microba Life Sciences' Net Debt Paydown Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #135 out of 198 companies for Net Debt Paydown Yield %. This places Microba Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Diagnostics & Research company?
A good Net Debt Paydown Yield % depends on the Medical Diagnostics & Research industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current Net Debt Paydown Yield % is -1.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 85.2% below its estimated fair value. The current Net Debt Paydown Yield % is -1.32%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Net Debt Paydown Yield % is -1.32% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 